评论戈麦斯等人的文章“对 Wasserman 等人（2018 年）文章的回应：对墨西哥使用 13 价肺炎球菌结合疫苗替代 10 价疫苗的持续使用进行建模”。
Comment on Gomez et. al. "Response to article by Wasserman et. al. (2018) 'Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico'".
机构信息
a Health Economics and Outcomes Research , Pfizer Inc , New York , NY , USA.
b Medical and Scientific Affairs , Pfizer Inc ., Mexico City , Mexico.
出版信息
Hum Vaccin Immunother. 2019;15(3):572-574. doi: 10.1080/21645515.2018.1558691. Epub 2019 Jan 18.
Abstract
In a recent Letter, Gomez et. al. provided a critique of our original analysis estimating the clinical and economic impact of switching from the 13-valent (PCV13) to the 10-valent (PCV10) pneumococcal conjugate vaccine in Mexico. This comment addresses Gomez et. al.'s comments with additional information and clarifies potential misinterpretations.
摘要
在最近的一封信中，Gomez 等人对我们最初的分析提出了批评，该分析估计了在墨西哥从 13 价（PCV13）到 10 价（PCV10）肺炎球菌结合疫苗的切换对临床和经济的影响。这篇评论用更多的信息回答了 Gomez 等人的意见，并澄清了潜在的误解。
相似文献
1
Comment on Gomez et. al. "Response to article by Wasserman et. al. (2018) 'Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico'".评论戈麦斯等人的文章“对 Wasserman 等人（2018 年）文章的回应：对墨西哥使用 13 价肺炎球菌结合疫苗替代 10 价疫苗的持续使用进行建模”。
Hum Vaccin Immunother. 2019;15(3):572-574. doi: 10.1080/21645515.2018.1558691. Epub 2019 Jan 18.
2
Response to article by Matthew Wasserman et al. (2018): "Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico".回复马修·瓦瑟曼等人（2018 年）的文章：“对墨西哥使用 13 价肺炎球菌结合疫苗与切换使用 10 价疫苗的持续使用进行建模”。
Hum Vaccin Immunother. 2019;15(3):570-571. doi: 10.1080/21645515.2018.1554974. Epub 2018 Dec 20.
3
Reply letter to "response to article by Johnna Perdrizet et al." by Gomez and colleagues.致 Gomez 等人对 Johnna Perdrizet 等人文章的回应的回复信。
Hum Vaccin Immunother. 2022 Dec 31;18(1):1917237. doi: 10.1080/21645515.2021.1917237. Epub 2021 Apr 28.
4
Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.丹麦和瑞典 10 价与 13 价肺炎球菌结合疫苗的成本效益分析。
Clin Ther. 2013 Feb;35(2):119-34. doi: 10.1016/j.clinthera.2012.12.006. Epub 2013 Jan 10.
5
Response to article by Johnna Perdrizet et al.,"Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants".对约翰娜·佩德里泽特等人所著文章《巴西婴儿用13价肺炎球菌结合疫苗（PCV13）替代10价肺炎球菌结合疫苗（PCV10）的成本效益分析》的回应
Hum Vaccin Immunother. 2022 Dec 31;18(1):1894898. doi: 10.1080/21645515.2021.1894898. Epub 2021 May 19.
6
Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong.马来西亚和香港地区婴儿普遍常规接种肺炎球菌疫苗的成本效益分析。
Hum Vaccin Immunother. 2016;12(2):403-16. doi: 10.1080/21645515.2015.1067351.
7
Choosing between 7-, 10- and 13-valent pneumococcal conjugate vaccines in childhood: a review of economic evaluations (2006-2014).儿童期7价、10价和13价肺炎球菌结合疫苗的选择：经济评估综述（2006 - 2014年）
Vaccine. 2015 Mar 30;33(14):1633-58. doi: 10.1016/j.vaccine.2015.01.081. Epub 2015 Feb 11.
8
Response to Wu et al. - Cost-effectiveness analysis of infant pneumococcal vaccination in Malaysia and Hong Kong.对吴等人的回应——马来西亚和香港婴儿肺炎球菌疫苗接种的成本效益分析
Hum Vaccin Immunother. 2016 Oct 2;12(10):2675-2680. doi: 10.1080/21645515.2016.1192738. Epub 2016 Jul 26.
9
Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands.13 价肺炎球菌结合疫苗的成本效益：德国、希腊和荷兰。
J Infect. 2012 Jan;64(1):54-67. doi: 10.1016/j.jinf.2011.10.015. Epub 2011 Nov 4.
10
[Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines].[基于13价肺炎球菌结合疫苗的墨西哥婴儿免疫计划的经济评估]
Value Health. 2011 Jul-Aug;14(5 Suppl 1):S65-70. doi: 10.1016/j.jval.2011.05.025.
引用本文的文献
1
Response to Gomez et al.'s Letter to the Editor Regarding: "Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants".对戈麦斯等人就《13价肺炎球菌结合疫苗（PCV13）与低价替代疫苗在菲律宾婴儿中的成本效益》致编辑信的回复。
Infect Dis Ther. 2022 Aug;11(4):1763-1765. doi: 10.1007/s40121-022-00641-9. Epub 2022 May 16.
本文引用的文献
1
Response to McGirr et al.'s Comment on "Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada".对麦吉尔等人就《加拿大13价肺炎球菌结合疫苗转为10价肺炎球菌结合疫苗对婴儿接种的临床和经济影响》一文的评论的回应。
Infect Dis Ther. 2018 Dec;7(4):539-543. doi: 10.1007/s40121-018-0221-2. Epub 2018 Nov 8.
2
Comment on: 'Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada', Wilson et al., 22 June 2018.评论：《加拿大13价肺炎球菌结合疫苗向10价肺炎球菌结合疫苗潜在转换对临床和经济的影响》，威尔逊等人，2018年6月22日。
Infect Dis Ther. 2018 Dec;7(4):535-538. doi: 10.1007/s40121-018-0220-3. Epub 2018 Nov 8.
3
Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Disease Caused by Serotype 3 in Children: A Systematic Review and Meta-analysis of Observational Studies.13 价肺炎球菌结合疫苗预防儿童血清型 3 引起的侵袭性疾病的有效性：系统评价和观察性研究的荟萃分析。
Clin Infect Dis. 2019 May 30;68(12):2135-2143. doi: 10.1093/cid/ciy920.
4
Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico.建立模型以比较 13 价肺炎球菌结合疫苗在墨西哥的持续使用与切换至 10 价疫苗的情况。
Hum Vaccin Immunother. 2019;15(3):560-569. doi: 10.1080/21645515.2018.1516491. Epub 2018 Sep 21.
5
Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK.动态传播建模以解决英国婴儿肺炎球菌结合疫苗接种计划的修改。
Epidemiol Infect. 2018 Oct;146(14):1797-1806. doi: 10.1017/S095026881800198X. Epub 2018 Jul 17.
6
Switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10: a defendable approach?将儿童肺炎球菌疫苗接种计划中的13价肺炎球菌结合疫苗（PCV13）更换为10价肺炎球菌结合疫苗（PCV10）：一种合理的方法？
Lancet Infect Dis. 2018 Aug;18(8):830-831. doi: 10.1016/S1473-3099(18)30346-3. Epub 2018 Jul 11.
7
Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada.加拿大13价肺炎球菌结合疫苗转为10价肺炎球菌结合疫苗用于婴儿接种的潜在临床和经济影响
Infect Dis Ther. 2018 Sep;7(3):353-371. doi: 10.1007/s40121-018-0206-1. Epub 2018 Jun 22.
8
Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland.10 价肺炎球菌结合疫苗对芬兰儿童侵袭性肺炎球菌病的长期影响。
Vaccine. 2018 Apr 5;36(15):1934-1940. doi: 10.1016/j.vaccine.2018.03.001. Epub 2018 Mar 8.
9
Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands.不同疫苗接种策略对减轻荷兰老年人肺炎球菌疾病负担的影响及成本效益
PLoS One. 2018 Feb 9;13(2):e0192640. doi: 10.1371/journal.pone.0192640. eCollection 2018.
10
Elucidating the impact of the pneumococcal conjugate vaccine programme on pneumonia, sepsis and otitis media hospital admissions in England using a composite control.使用复合对照法阐明肺炎球菌结合疫苗计划对英格兰肺炎、败血症和中耳炎住院率的影响。
BMC Med. 2018 Feb 8;16(1):13. doi: 10.1186/s12916-018-1004-z.
Zotero 插件